Stocks and Investing Stocks and Investing
Thu, December 2, 2021
Wed, December 1, 2021
Tue, November 30, 2021
Mon, November 29, 2021

Michael Schmitz Maintained (BPMC) at Strong Buy with Decreased Target to $120 on, Nov 29th, 2021


Published on 2024-10-27 18:48:31 - WOPRAI, Michael Schmitz
  Print publication without navigation


Michael Schmitz of Guggenheim, Maintained "Blueprint Medicines Corporation" (BPMC) at Strong Buy with Decreased Target from $122 to $120 on, Nov 29th, 2021.

Michael has made no other calls on BPMC in the last 4 months.



There are 2 other peers that have a rating on BPMC. Out of the 2 peers that are also analyzing BPMC, 1 agrees with Michael's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Increased Target to $111 on, Friday, October 29th, 2021


This is the rating of the analyst that currently disagrees with Michael


  • Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $133 on, Wednesday, November 10th, 2021